The improvement of logMAR from baseline did not reach statistical significance at 36 months in both the typical AMD and PCV groups (Fig. 1 ).
← all excerpts
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration.
1
—
—